Klotho Neurosciences Enters Material Agreement, Reports Financial Obligations
Ticker: GRMLW · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1907223
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: KLTO
TL;DR
Klotho Neurosciences just signed a big deal and has new financial obligations. Watch KLTO.
AI Summary
Klotho Neurosciences, Inc. announced on January 23, 2025, that it entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. This filing follows a name change from Redwoods Acquisition Corp. in 2022 and ANEW Medical, Inc. in 2024.
Why It Matters
This 8-K filing indicates significant financial and contractual developments for Klotho Neurosciences, Inc., potentially impacting its operational and financial standing.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Klotho Neurosciences, Inc. (company) — Registrant
- Redwoods Acquisition Corp. (company) — Former Company Name
- ANEW Medical, Inc. (company) — Former Company Name
- January 23, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Klotho Neurosciences, Inc.?
The filing states that Klotho Neurosciences, Inc. entered into a material definitive agreement on January 23, 2025, but the specific details of this agreement are not provided in the provided text.
What type of direct financial obligation was created by Klotho Neurosciences, Inc.?
The filing indicates the creation of a direct financial obligation by Klotho Neurosciences, Inc. on January 23, 2025, but the specific details of this obligation are not disclosed in the provided text.
When did Klotho Neurosciences, Inc. change its name from ANEW Medical, Inc.?
The filing states that the former company name was ANEW Medical, Inc. and the date of the name change was June 24, 2024.
What is the SIC code for Klotho Neurosciences, Inc.?
The Standard Industrial Classification (SIC) code for Klotho Neurosciences, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What are the key items reported in this 8-K filing?
This 8-K filing reports on the entry into a material definitive agreement, the creation of a direct financial obligation, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 1,325 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2025-01-23 19:05:59
Key Financial Figures
- $2,000,000 — ase, for an aggregate purchase price of $2,000,000, two senior convertible promissory note
- $2,173,914 — ny in the aggregate principal amount of $2,173,914 and two warrants (the "Warrants") to pu
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the "Common Stock"), in each
- $1,086,957 — e first Note in the principal amount of $1,086,957 (the "First Note") and the first Warran
- $1,000,000 — ock, for an aggregate purchase price of $1,000,000. The Notes mature on the anniversary o
- $0.25 — to shares of Common Stock at a price of $0.25 per share (the "Conversion Price"); pro
- $0 — e Company at an exercise price equal to $0.50, subject to adjustment for any stock
Filing Documents
- ea0228576-8k_klotho.htm (8-K) — 34KB
- ea022857601ex4-1_klotho.htm (EX-4.1) — 254KB
- ea022857601ex4-2_klotho.htm (EX-4.2) — 267KB
- ea022857601ex4-3_klotho.htm (EX-4.3) — 120KB
- ea022857601ex4-4_klotho.htm (EX-4.4) — 106KB
- ea022857601ex4-5_klotho.htm (EX-4.5) — 46KB
- 0001213900-25-006105.txt ( ) — 1247KB
- klto-20250123.xsd (EX-101.SCH) — 3KB
- klto-20250123_def.xml (EX-101.DEF) — 26KB
- klto-20250123_lab.xml (EX-101.LAB) — 36KB
- klto-20250123_pre.xml (EX-101.PRE) — 25KB
- ea0228576-8k_klotho_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 23, 2025 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 3